Investing.com -- LifeMD Inc (NASDAQ:LFMD) stock surged 14.9% after the virtual primary care provider announced it is now offering Novo Nordisk’s (NYSE:NVO) Wegovy pill through its telehealth platform. The oral semaglutide medication is the first FDA-approved GLP-1 pill for weight management.
The company is offering eligible patients access to the Wegovy pill for as little as $149 per month, expanding its portfolio of branded obesity treatments. This move broadens LifeMD’s existing collaboration with Novo Nordisk, with LifeMD featured on NovoCare and Wegovy websites as a trusted telehealth provider.
"In close collaboration with Novo Nordisk, we moved quickly to bring the Wegovy pill to patients through LifeMD at the attractive cash-pay price, reinforcing our role as a preferred virtual destination for evidence-based medical weight management," said Justin Schreiber, Chairman and CEO of LifeMD.
The news also lifted other companies in the weight management space. WW International Inc (NASDAQ:WW), formerly Weight Watchers, rose 7.2% after announcing it would also offer the Wegovy pill through its integrated GLP-1 platform starting at $149 per month. Meanwhile, GoodRx Holdings Inc (NASDAQ:GDRX) gained 3.8% following its announcement that the pill would be available at a $149 monthly cash price at over 70,000 pharmacies nationwide.
The FDA approved Novo Nordisk’s Wegovy pill on December 22, 2025, as the first oral GLP-1 therapy for weight management and cardiovascular health. In clinical trials, patients achieved 16.6% mean weight loss versus 2.7% with placebo over 64 weeks.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.































